260 related articles for article (PubMed ID: 37146271)
1. Drugs activating hypoxia-inducible factors correct erythropoiesis and hepcidin levels via renal EPO induction in mice.
Nakai T; Iwamura Y; Kato K; Hirano I; Matsumoto Y; Tomioka Y; Yamamoto M; Suzuki N
Blood Adv; 2023 Aug; 7(15):3793-3805. PubMed ID: 37146271
[TBL] [Abstract][Full Text] [Related]
2. The drug-specific properties of hypoxia-inducible factor-prolyl hydroxylase inhibitors in mice reveal a significant contribution of the kidney compared to the liver to erythropoietin induction.
Nakai T; Saigusa D; Kato K; Fukuuchi T; Koshiba S; Yamamoto M; Suzuki N
Life Sci; 2024 Jun; 346():122641. PubMed ID: 38614299
[TBL] [Abstract][Full Text] [Related]
3. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis.
Liu Q; Davidoff O; Niss K; Haase VH
J Clin Invest; 2012 Dec; 122(12):4635-44. PubMed ID: 23114598
[TBL] [Abstract][Full Text] [Related]
5. Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia.
Kapitsinou PP; Liu Q; Unger TL; Rha J; Davidoff O; Keith B; Epstein JA; Moores SL; Erickson-Miller CL; Haase VH
Blood; 2010 Oct; 116(16):3039-48. PubMed ID: 20628150
[TBL] [Abstract][Full Text] [Related]
6. Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors
Yang J; Xing J; Zhu X; Xie X; Wang L; Zhang X
Front Endocrinol (Lausanne); 2023; 14():1131516. PubMed ID: 37008953
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease.
Kurata Y; Tanaka T; Nangaku M
Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):414-422. PubMed ID: 32452915
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors and Iron Metabolism.
Ogawa C; Tsuchiya K; Maeda K
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769359
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages.
Mima A
Eur J Pharmacol; 2021 Dec; 912():174583. PubMed ID: 34678238
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
Souza E; Cho KH; Harris ST; Flindt NR; Watt RK; Pai AB
Expert Opin Investig Drugs; 2020 Aug; 29(8):831-844. PubMed ID: 32476498
[TBL] [Abstract][Full Text] [Related]
11. Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents.
Weir MR
Am J Nephrol; 2021; 52(6):450-466. PubMed ID: 34280923
[TBL] [Abstract][Full Text] [Related]
12. Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients.
Wang B; Yin Q; Han YC; Wu M; Li ZL; Tu Y; Zhou LT; Wei Q; Liu H; Tang RN; Cao JY; Lv LL; Liu BC
Ren Fail; 2020 Nov; 42(1):912-925. PubMed ID: 32869703
[TBL] [Abstract][Full Text] [Related]
13. Stabilizing Hypoxia-Inducible Factor to Manage Anemia in Chronic Kidney Disease: From Basic Theory to Clinical Study.
Wang Y; Yu X
Kidney Dis (Basel); 2024 Apr; 10(2):132-142. PubMed ID: 38659701
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in maintenance dialysis: a meta-analysis.
Wu M; Zang C; Ma F; Chen B; Liu J; Xu Z
Clin Exp Nephrol; 2022 Nov; 26(11):1043-1054. PubMed ID: 36006596
[TBL] [Abstract][Full Text] [Related]
15. EPO synthesis induced by HIF-PHD inhibition is dependent on myofibroblast transdifferentiation and colocalizes with non-injured nephron segments in murine kidney fibrosis.
Kobayashi H; Davidoff O; Pujari-Palmer S; Drevin M; Haase VH
Acta Physiol (Oxf); 2022 Aug; 235(4):e13826. PubMed ID: 35491502
[TBL] [Abstract][Full Text] [Related]
16. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
[TBL] [Abstract][Full Text] [Related]
17. A single approach to targeting transferrin receptor 2 corrects iron and erythropoietic defects in murine models of anemia of inflammation and chronic kidney disease.
Olivari V; Di Modica SM; Lidonnici MR; Aghajan M; Cordero-Sanchez C; Tanzi E; Pettinato M; Pagani A; Tiboni F; Silvestri L; Guo S; Ferrari G; Nai A
Kidney Int; 2023 Jul; 104(1):61-73. PubMed ID: 36990212
[TBL] [Abstract][Full Text] [Related]
18. Erythropoietin's inhibiting impact on hepcidin expression occurs indirectly.
Gammella E; Diaz V; Recalcati S; Buratti P; Samaja M; Dey S; Noguchi CT; Gassmann M; Cairo G
Am J Physiol Regul Integr Comp Physiol; 2015 Feb; 308(4):R330-5. PubMed ID: 25519735
[TBL] [Abstract][Full Text] [Related]
19. Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors.
Sugahara M; Tanaka T; Nangaku M
Pharmacol Ther; 2022 Nov; 239():108272. PubMed ID: 36031160
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease.
Haase VH
Kidney Int Suppl (2011); 2021 Apr; 11(1):8-25. PubMed ID: 33777492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
